Opinion

Video

Managing Hematologic AEs Associated with ADC Treatments

Author(s):

VK Gadi, MD, PhD,Susana M. Campos, MD, MPH

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Related Videos
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.
2 expert is featured in this series.
4 experts are featured in this series.
2 experts in this video
Related Content
Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 6th 2025

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

NHL stock.adobe.com
December 27th 2024

New Advances in Waldenström Macroglobulinemia

Narjust Florez, MD
September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

Maximilian Stahl, MD
December 18th 2024

Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML